TRADING
IN NOVEN COMMON STOCK HALTED |
BackMiami, FL, December
2, 2005 -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) announced that
NASDAQ has halted trading of Noven common stock effective this morning,
December 2, 2005. The Psychopharmacologic Drugs Advisory Committee
to the U.S. Food and Drug Administration (FDA) meets today to review
and discuss the amended New Drug Application for Daytrana™ (methylphenidate
transdermal system).
Daytrana™, licensed globally to Shire plc, is an investigational
transdermal patch designed for once-daily use to treat attention deficit
hyperactivity disorder (ADHD) in children aged 6 to 12 years.
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a
leading developer of advanced transdermal drug delivery technologies
and prescription transdermal products. Noven's prescription patches
are sold in over 30 countries, and a range of new patches are being
developed in collaboration with Shire plc, Novartis Pharma AG, P&G
Pharmaceuticals, Endo Pharmaceuticals Inc. and others. See www.noven.com
for additional information.
| Contact: Joseph C. Jones Vice President – Corporate Affairs (305) 253-1916 |
Copyright © 2005 Noven Pharmaceuticals, Inc. All rights reserved.